R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.
Market Access Weight loss treatments bring in billions but capacity remain... The high demand for weight loss treatments has made their rollout a staggered process.
R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.
Patients Why medical weight loss is more complicated than GLP-1s A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.
R&D GLP-1 weight loss drugs: An overview and update GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are dramatically changing the field of medically-assisted weight loss.
News Incyte blocks US launch of Sun Pharma's alopecia drug A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.